In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 201 to 250 of 375

TitleTypeExpected publication date
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]Technology appraisal guidanceTBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidance
Neonatal infection: antibiotics for prevention and treatment - updateNICE guideline
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]Technology appraisal guidance
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Technology appraisal guidanceTBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]Technology appraisal guidanceTBC
Nirogacestat for treating desmoid tumours [ID6453]Technology appraisal guidance
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]Technology appraisal guidanceTBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]Technology appraisal guidanceTBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]Technology appraisal guidance
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Technology appraisal guidanceTBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidanceTBC
NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]Technology appraisal guidanceTBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]Technology appraisal guidance
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]Technology appraisal guidanceTBC
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and managementNICE guideline
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]Technology appraisal guidance
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]Technology appraisal guidanceTBC
Optical Coherence Tomography to guide percutaneous coronary interventionInterventional procedures guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
Orforglipron for managing overweight and obesity [ID6516]Technology appraisal guidance
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]Technology appraisal guidanceTBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)NICE guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Technology appraisal guidanceTBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Technology appraisal guidance
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]Technology appraisal guidanceTBC
Peezy Midstream for urine collection (MT446)Medical technologies guidanceTBC
Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]Technology appraisal guidanceTBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Technology appraisal guidance
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]Technology appraisal guidanceTBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]Technology appraisal guidanceTBC
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All